CEBPA and acute myeloid leukemia: To assess the prognostic significance of clinical and molecular variables, univariate and multivariate COX regression analyses were conducted, encompassing expression levels of AK1 (high vs. low), age (≥60 years vs. <60 years), peripheral WBC count (≥20 × 109/l vs. <20 × 109/l), FLT3-ITD (positive vs. negative), and frequent AML genetic mutations (FLT3-ITD, NPM1, CEBPA, RUNX1, ASXL1, TP53, DNMT3A, IDH1/IDH2, and TET2; mutated vs. wild type).